DSGN DESIGN THERAPEUTICS INC

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York.

A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be archived for at least 30 days following the presentation.

About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:

Renee Leck

THRUST Strategic Communications



EN
13/05/2025

Underlying

DSGNDESIGN THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DESIGN THERAPEUTICS INC

 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-8...

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)  Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) Ongoing Cash and Securities of $206.0 Million as of Third Quarter 2025 Support Continued Pipeline Advancement CARLSBAD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Design Thera...

10h / 3m 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.45
XNCR XENCOR INC.
SCHL Scholastic Corp... ... (+35)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

XNCR XENCOR INC.
SCHL SCHOLASTIC CORPORATION
MRCY MERCURY SYSTEMS INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
KURA KURA ONCOLOGY INC.
JACK JACK IN THE BOX INC.
INTC INTEL CORPORATION
HELE HELEN OF TROY LIMITED
CROX CROCS INC.
AIR AAR CORP.
UNFI UNITED NATURAL FOODS INC.
LINK INTERLINK ELECTRONICS
SRRK SCHOLAR ROCK HOLDING CORPORATION
STOK STOKE THERAPEUTICS
IMTX IMMATICS N V (A)
KYMR KYMERA THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
COGT COGENT BIOSCIENCES INC
RLAY RELAY THERAPEUTICS
HIMS HIMS AND HERS HEALTH INC (A)
VERA VERA THERAPEUTICS INC
TNGX TANGO THERAPEUTICS INC
DSGN DESIGN THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
MBC_w MASTERBRAND INC
IRON DISC MEDICINE INC
CTNM CONTINEUM THERAPEUTICS INC
PACS PACS GROUP INC
ZBIO ZENAS BIOPHARMA INC.
UPB UPSTREAM BIO INC
MIR MIRION TECHNOLOGIES INC
SION SIONNA THERAPEUTICS INC
KLRS KALARIS THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
EMPG EMPRO GROUP INC
09/29/25 September 29, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Appoints Justin Gover to Board of Directors

Design Therapeutics Appoints Justin Gover to Board of Directors CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two decades, from inc...

September 10, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.45
FICO FAIR ISAAC CORP...
PSTG Pure Storage I... ... (+25)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

FICO FAIR ISAAC CORPORATION
PSTG PURE STORAGE INC. CLASS A
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
NTAP NETAPP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
A AGILENT TECHNOLOGIES INC.
AGX ARGAN INC.
ELF E.L.F. BEAUTY INC.
CHCI COMSTOCK HOLDING COMPANIES
RCMT RCM TECHNOLOGIES
STNE STONECO
CSTL CASTLE BIOSCIENCES
SOFI SOFI TECHNOLOGIES INC
IMRX IMMUNEERING CORP
DSGN DESIGN THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
ASPI ASP ISOTOPES INC
FTREV FORTREA HOLDINGS INC.
KRRO KORRO BIO INC
RAPP RAPPORT THERAPEUTICS INC
ALMU AELUMA INC
RHLD RESOLUTE HOLDINGS MANAGEMENT INC
ASST ASSET ENTITIES INC
SNDK SANDISK CORP
INFU MULTI UNITS LU - AMUNDI US INFLATION EXPECTATIONS 10Y
08/29/25 August 29, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics to Participate in the 2025 Cantor Global Healthcar...

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be...

August 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch